A detailed history of Slagle Financial, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Slagle Financial, LLC holds 44,642 shares of BMY stock, worth $2.37 Million. This represents 0.95% of its overall portfolio holdings.

Number of Shares
44,642
Previous 41,030 8.8%
Holding current value
$2.37 Million
Previous $2.23 Billion 16.68%
% of portfolio
0.95%
Previous 1.21%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024

BUY
$40.25 - $52.99 $145,383 - $191,399
3,612 Added 8.8%
44,642 $1.85 Billion
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $618,654 - $701,433
-12,894 Reduced 23.91%
41,030 $2.23 Billion
Q4 2023

Mar 05, 2024

BUY
$48.48 - $57.85 $1.35 Million - $1.61 Million
27,774 Added 106.21%
53,924 $1.39 Billion
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $141,251 - $157,941
2,440 Added 10.29%
26,150 $1.52 Billion
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $1.51 Million - $1.68 Million
23,710 New
23,710 $1.52 Billion

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Slagle Financial, LLC Portfolio

Follow Slagle Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Slagle Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Slagle Financial, LLC with notifications on news.